The pharmacokinetic, pharmacodynamic and pharmacogenomic outcomes of reduced dosage of efavirenz: the Encore1 study

减少依非韦伦剂量的药代动力学、药效学和药物基因组学结果：Encore1 研究

• 批准号: nhmrc : 1048402
• 负责人: Dr Alan Winston
• 金额: $ 82.35万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/pharmacokinetic-pharmacodynamic-pharmacogenomic-encore1-study/112018
• 关键词: pharmacokinetic; pharmacodynamic; pharmacogenomic; outcomes; reduced

Our primary aim is to assess blood concentrations of a drug called efavirenz, an important drug used in the treatment of HIV infection and associate these with variability of genes that control metabolism of the drug. A better understanding of gene variability and how it relates to safety and efficacy outcomes at a reduced, compared to a standard dose of efavirenz could support improved treatment of HIV disease.

我们的主要目的是评估依非韦伦（efavirenz）药物的血液浓度，这是一种用于治疗艾滋病毒感染的重要药物，并将其与控制药物代谢的基因变异联系起来。与标准剂量的依非韦伦相比，更好地了解基因变异性及其与安全性和疗效结果的关系可以支持改善艾滋病毒疾病的治疗。